E-LIB Suche - Ergebnisse für: Fajac, I.

1

P046 Lenticlair™-ON: An extension trial examining long-term..:

Davies, J.C. ; Mall, M.A. ; Polineni, D....
Journal of Cystic Fibrosis. 23 (2024) - p. S80 , 2024

Link: https://doi.org/10.1016/..

2

ECFS standards of care on CFTR-related disorders: Towards a..:

De Wachter, E ; De Boeck, K ; Sermet-Gaudelus, I...
Journal of Cystic Fibrosis. 23 (2024) 3 - p. 388-397 , 2024

Link: https://doi.org/10.1016/..

3

P481 MRI as a follow-up to lung CT to evaluate suspicious l..:

Wucherpfennig, L. ; Wielpütz, M.O. ; Salvatore, M....
Journal of Cystic Fibrosis. 23 (2024) - p. S116 , 2024

Link: https://doi.org/10.1016/..

4

WS11.04 Evaluation of lung computed tomography screening of..:

Di Mango, E. ; Engel, A.T. ; Fajac, I....
Journal of Cystic Fibrosis. 23 (2024) - p. S21 , 2024

Link: https://doi.org/10.1016/..

5

WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivaca..:

Castellani, C. ; Mondejar-Lopez, P. ; Quon, B.S....
Journal of Cystic Fibrosis. 23 (2024) - p. S11 , 2024

Link: https://doi.org/10.1016/..

6

P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety..:

Davies, J.C. ; Mall, M.A. ; Polineni, D....
Journal of Cystic Fibrosis. 23 (2024) - p. S80 , 2024

Link: https://doi.org/10.1016/..

7

AQP5 , a second gene at play with CFTR in aquagenic palmopl..:

Sperelakis-Beedham, B ; Lopez, M ; Bourrat, E...
info:eu-repo/semantics/altIdentifier/doi/10.1111/jdv.18869. , 2023

Link: https://hal.science/hal-..

8

AQP5 , a second gene at play with CFTR in aquagenic palmopl..:

Sperelakis-Beedham, B ; Lopez, M ; Bourrat, E...
info:eu-repo/semantics/altIdentifier/doi/10.1111/jdv.18869. , 2023

Link: https://hal.science/hal-..

9

AQP5 , a second gene at play with CFTR in aquagenic palmopl..:

Sperelakis-Beedham, B ; Lopez, M ; Bourrat, E...
info:eu-repo/semantics/altIdentifier/doi/10.1111/jdv.18869. , 2023

Link: https://hal.science/hal-..

10

AQP5 , a second gene at play with CFTR in aquagenic palmopl..:

Sperelakis-Beedham, B ; Lopez, M ; Bourrat, E...
info:eu-repo/semantics/altIdentifier/doi/10.1111/jdv.18869. , 2023

Link: https://hal.science/hal-..

11

Standards for the care of people with cystic fibrosis; esta..:

Southern, K ; Addy, C ; Bell, S...
https://discovery.ucl.ac.uk/id/eprint/10184881/1/1-s2.0-S1569199323017277-main.pdf. , 2023

Link: https://discovery.ucl.ac..

12

185 Long-term safety and efficacy of elexacaftor/tezacaftor..:

Chmiel, J. ; Barry, P.J. ; Colombo, C....
Journal of Cystic Fibrosis. 21 (2022) - p. S108-S109 , 2022

Link: https://doi.org/10.1016/..

13

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aqu..:

Girodon, E. ; Lopez, M. ; Sperelakis-Beedham, B....
Journal of Cystic Fibrosis. 21 (2022) - p. S41 , 2022

Link: https://doi.org/10.1016/..

14

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in..:

Davies, J ; Goss, C ; Fajac, I...
European Respiratory Journal. , 2021

Link: http://hdl.handle.net/10..

15

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Re..:

Barry, P.J ; Mall, M.A ; Álvarez, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982185/. , 2021

Link: http://www.ncbi.nlm.nih...